The in vitro antibacterial activity of OPC-17116, a new fluoroquinolone, against a wide variety of clinical isolates was evaluated and compared with those of ciprofloxacin, ofloxacin, and norfloxacin. OPC-17116 showed potent broad-spectrum activity against gram-positive and -negative bacteria. The activity of this compound against gram-positive bacteria was higher than those of other quinolones, and its activity against gram-negative and anaerobic bacteria was roughly comparable to those of other quinolones. OPC-17116 had potent activity against important pathogens of respiratory tract infections such as Staphylococcus aureus, Streptococcus pneumoniae, KiebsieUla pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, and BranhameUla catarrhalis. The MICs of this compound against 90% of these organisms, except for methicillinresistant S. aureus, ranged from _0.006 to 3.13 ,ug/ml. OPC-17116 at more than one-half the MICs was bactericidal against clinical isolates of S. aureus, Escherichia coil, K. pneumoniae, and P. aeruginosa. The activity of OPC-17116 was decreased by several culture conditions such as acidic pH, high concentration of Mg2e ions, and inoculum size of 107 CFU/ml. OPC-17116 inhibited the supercoiling activity of DNA gyrases from E. coli KL-16 and S. aureus SA113 (50%6 inhibitory concentrations, 0.19 and 23.0 ,iLgIml, respectively).
Mg2e ions, and inoculum size of 107 CFU/ml. OPC-17116 inhibited the supercoiling activity of DNA gyrases from E. coli KL-16 and S. aureus SA113 (50%6 inhibitory concentrations, 0.19 and 23.0 ,iLgIml, respectively).
The amount of OPC-17116 accumulation was higher than that of other quinolones in S. aureus.
A number of new quinolone antibacterial agents such as norfloxacin (12) , ofloxacin (22) , and ciprofloxacin (27) have been developed and introduced into the market. These drugs have broad spectra and potent activities against gram-positive and gram-negative bacteria.
OPC-17116 [(+)-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinoline carboxylic acid hydrochloride] is a new quinolone antibacterial agent synthesized at Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan. This compound has one methyl residue at the 5 position of the quinolone core and one at the 3 position of the piperazine moiety. In an earlier study (10) , in which this agent was compared with ofloxacin, enoxacin, ciprofloxacin, and tosufloxacin, good in vitro and in vivo activities were demonstrated. Those researchers also reported that the peak level of OPC-17116 in the lungs of mice was significantly higher than the levels in lungs achieved with an equivalent dose of other quinolones. In this report, we describe the in vitro antibacterial activity, bactericidal activity, and inhibition of DNA gyrase supercoiling activity of OPC-17116 in comparison with those of ciprofloxacin, ofloxacin, and norfloxacin. Furthermore, we report the amounts of uptake of these quinolones in Staphylococcus aureus.
MATERIALS AND METHODS Drugs. OPC-17116 was provided by Otsuka Pharmaceutical Co. The other drugs used in the experiment were obtained from the following sources: ciprofloxacin, Bayer Yakuhin, Ltd., Osaka, Japan; ofloxacin, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan; norfloxacin, Kyorin Pharma-* Corresponding author. t Present address: Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., Kagasuno, Kawauchi-cho, Tokushima 771-01 Japan.
ceutical Co., Ltd., Tokyo, Japan; methicillin, Banyu Pharmaceutical Co., Ltd., Tokyo, Japan.
Organisms. Bacterial strains used in this study were reference strains and clinical isolates collected from several hospitals and laboratories in Japan between 1985 and 1990. All isolates were maintained at the Episome Institute.
Susceptibility tests. The antibacterial activities of the drugs were determined by the twofold agar dilution method with Sensitivity Disk Agar-N (SDA; Nissui Pharmaceutical, Tokyo, Japan), which is modified Mueller-Hinton agar, unless specified otherwise. SDA supplemented with 10% defibrinated horse blood and 5% Fildes enrichment (Difco Laboratories, Detroit, Mich.) was used for growth of streptococci and Haemophilus influenzae, respectively. GC agar (Difco) supplemented with 1% IsoVitaleX (BBL Microbiology Systems, Cockeysville, Md.) was used for Neisseria gonorrhoeae. GAM agar (Nissui) was used for obligate anaerobes. Overnight broth cultures of the bacterial strains were diluted with corresponding fresh broth to a final concentration of approximately 106 CFU/ml, and an inoculum of 104 CFU per spot was applied with an inoculating apparatus (Microplanter; Sakuma Seisakusho, Tokyo, Japan) to agar plates containing graded concentrations of drug. The plates were incubated at 37°C for 18 h except for N. gonorrhoeae, which was incubated in a candle jar, and obligate anaerobes, which were incubated in an anaerobic chamber. The MIC was defined as the lowest concentration of drug that inhibited visible growth on the plate.
Determination of bactericidal activity. Bactericidal activities of drugs were determined by MBC and time-kill studies as described previously (14) . Overnight cultures of bacterial strains, for which sensitivity test broth (Nissui) was used, were diluted with fresh sensitivity test broth to about 106 CFU/ml, and 1.8 ml of the dilution was added to 0.2 ml of the drug solution in a clear tube and incubated without shaking for 18 h. After determination of the MIC, 0.1 ml of the (7) was prepared by the method described in a previous report (21) , and that from S. aureus SA113 (11) was also prepared by the method described in a previous report (19) . In short, S. aureus cells were treated with lysostaphin and lysozyme (Sigma Chemical Co., St. Louis, Mo.), and 1 M NaCl in cell lysate was added for extraction of the enzyme from DNA. After precipitation of DNA by Po}ymin P (Bethesda Research Laboratories, Ltd.), the crude cell extract was loaded on a novobiocin-Sepharose column (23) , and fractions of DNA gyrase subunits A and B were obtained. The reaction conditions for DNA supercoiling activity were performed according to the modifications described in previous reports (5, 6, 18) . One unit of enzyme activity was defined as the amount that converts 50% of relaxed pBR322 DNA to the supercoiled form at 37°C for 60 min as detected by agarose gel electrophoresis. The specific activities of purified subunits A and B from S. aureus SA113 hydrochloride (pH 7.8), 20 mM KCl, 2 mM MgCl2, 2 mM spermidine, 1.5 mM ATP, 1 mM dithiothreitol, 30 ,ug of tRNA per ml, 15 p,g of bovine serum albumin per ml, 10 ,ug of relaxed pBR322 DNA per ml, 1 U each of DNA gyrase subunits A and B, and appropriate drug solutions. The concentration of KCl was changed to 100 mM in studies with gyrase isolated from S. aureus. After 60 min of incubation at 37°C, the reaction was stopped by the addition of 3 ,ul of proteinase K (1 mg/ml; Sigma). The mixture was subjected to electrophoresis in a 0.8% agarose gel. The gel was stained in 0.5 ,ug of ethidium bromide per ml and photographed upon exposure to a UV transilluminator. The 50% inhibitory dose (IC50) for supercoiling activity was determined by using a densitometric assay as described previously (1) .
Measurement of cell-associated drug in S. aureus. The uptake of ciprofloxacin, norfloxacin, ofloxacin, and OPC-17116 by S. aureus was examined by the method described in previous reports (8, 29) . In this study, we used two strains, S. aureus SA113, which is susceptible to all quinolones, and S. aureus MS16401, which shows high-level resistance to norfloxacin (MIC, 100 ,g/ml) and low-level resistance to ciprofloxacin and ofloxacin (MICs, 12.5 and 3.13 ,ug/ml, respectively) but susceptibility to OPC-17116 (MIC, 0.39 ,ug/ml). The quinolones were added to a final concentration of 10 ,ug/ml and incubated at 37°C for 20 min. Amounts of cell-associated quinolones were measured by high-performance liquid chromatography (Irica Instruments Inc., Kyoto, Japan) with a YMCA-312 column (Yamamura Chemical Laboratories Co., Ltd., Kyoto, Japan). The mobile phases were 5% acetic acid-methanol-acetonitrile ( Bactericidal activity. The bactericidal activities of OPC-17116 were compared with those of ciprofloxacin and ofloxacin. For the determination of MBCs, we used 10 clinical strains each of S. aureus, E. coli, K pneumoniae, and P. aeruginosa ( Table 2 ). The MBCs of OPC-17116, ciprofloxacin, and ofloxacin were equal to or only twice the respective MICs. The killing curve study was performed with S. aureus Smith, E. coli ML4707, and P. aeruginosa GN11189 (Fig. 1) . A rapid decrease in the number of viable cells was observed at concentrations above one-half the MIC with all strains; all quinolones tested showed the same result. The effects on activity of alternating pH are shown in Table 3 . The activity of OPC-17116 at pH 6.0 was less than that at pH 7.0 against all of the strains tested. The activity at pH 8.0 was the same or slightly better than that at pH 7.0. These results were also obtained with the other quinolones tested (data not shown).
The effect of Mg2" on the activity of OPC-17116 is shown in Table 5 . There was a slight increase in the MICs at an inoculum of 107 CFU/ml compared with MICs at an inoculum of 105 CFUI/ml.
Inhibitory effect on DNA gyrase. The IC50s for supercoiling activities of E. coli KL-16 and S. aureus SA113 DNA gyrases are shown in Table 6 . The inhibitory effect of OPC-17116 against E. coli was twofold less than that of ciprofloxacin and about twofold more than those of ofloxacin and norfloxacin. The IC50s of the drugs tested correlated well with their respective MICs. On the other hand, the IC50s of OPC-17116, ciprofloxacin, and ofloxacin in S. aureus were 23.0, 20.5, and 27.0 ,ug/ml, respectively, which were not parallel to the MICs.
Measurement of cell-associated drug in S. aureus. The amounts of cell-associated drug are shown in Table 7 . The amounts of cell-associated drug in strain MS16401 were lower than those in SA113 with all quinolones tested. The amounts of cell-associated OPC-17116 in both strains were two-to fivefold higher than those of the other quinolones.
DISCUSSION
OPC-17116, a new quinolone antibacterial agent that demonstrated a broad spectrum and potent antibacterial activity against many gram-positive and gram-negative organisms, was tested in this study.
Like other quinolones, OPC-17116 was bactericidal against clinical isolates (Table 2 ) and rapidly killed the bacterial cells of standard strains at concentrations above one-half the MIC (Fig. 1) . OPC-17116 was less active at an acidic pH than at a neutral pH, and its activity was lowered in the presence of high Mg2+ concentrations, as was observed with other quinolones (2) . Furthermore, we showed that inoculum size affected the activity of OPC-17116 (Table  5 ). The degree of MIC increase at 107 CFU/ml compared with MICs at 103 and 105 CFU/ml was particularly noticeable with Serratia marcescens and P. aeruginosa. The same (Table 7) . We infer from this that antibacterial activity against gram-positive bacteria could be affected not only by the inhibition of DNA gyrase but also by the extent of accumulation of drug in the cells.
The emergence of MRSA has become a serious problem in the 1980s (13, 15, 25) . Furthermore, after introduction of quinolone antibacterial agents for clinical use, MRSA rapidly acquired resistance to those agents as well (3, 16, 17 (10, 20) . OPC-17116 also showed good therapeutic efficacy in respiratory tract infections in an experimental animal model (10, 20) . If this characteristic of OPC-17116 applies to humans, OPC-17116 may become an effective drug against respiratory tract infections. To determine the therapeutic role of OPC-17116, further clinical study is warranted.
